Basic and clinical studies on fleroxacin in urological infections

Yoshio Nishitani; Satoshi Uno; Daisuke Yamada; Yoshitsugu Nasu; Syunji Hayata; Masaya Tsugawa; Hiromi Kumon; Hiroyuki Ohmori

doi:10.11250/chemotherapy1953.38.Supplement2_531

Basic and clinical studies on fleroxacin in urological infections

Yoshio Nishitani, Satoshi Uno, Daisuke Yamada, Yoshitsugu Nasu, Syunji Hayata, Masaya Tsugawa, Hiromi Kumon, Hiroyuki Ohmori

Research output: Contribution to journal › Article › peer-review

1 Citation (Scopus)

Abstract

We studied the antibacterial activity and clinical utility of fleroxacin, a new oral fluoroquinolone, in urological infections. 1. Antibacterial activity: the MICs of fleroxacin against clinical isolates (185 strains of 12 species) from urinary tract infections, were compared with those of ofloxacin (OFLX) and norfloxacin (NFLX). Except against P.aeruginosa, the overall antibacterial activity of fleroxacin was excellent and similar to that of NFLX. 2. Clinical efficacy: the overall clinical efficacy according to the criteria of the Japanese UTI Committee was 100%(1/1) in acute uncomplicated cystitis and 75.6%(31/41) in chronic complicated UTI. Bacteriologically, 36 of 45 strains (80.0%) were eradicated. 3. Side effects: facial hot flushes were noted in one patient, but the symptom was mild and transient. With regard to laboratory findings, slight and transient elevations of GOT and GPT and of BUN and s-Cr were seen in one patient.

Original language	English
Pages (from-to)	531-538
Number of pages	8
Journal	CHEMOTHERAPY
Volume	38
DOIs	https://doi.org/10.11250/chemotherapy1953.38.Supplement2_531
Publication status	Published - Jan 1 1990

Keywords

Fleroxacin

ASJC Scopus subject areas

Pharmacology (medical)
Infectious Diseases
Pharmacology
Drug Discovery
Oncology

UN SDGs

This output contributes to the following Sustainable Development Goal(s)

Access to Document

10.11250/chemotherapy1953.38.Supplement2_531

Fingerprint Dive into the research topics of 'Basic and clinical studies on fleroxacin in urological infections'. Together they form a unique fingerprint.

Cite this

@article{ee20640ada1549469744d215b3afb65a,

title = "Basic and clinical studies on fleroxacin in urological infections",

abstract = "We studied the antibacterial activity and clinical utility of fleroxacin, a new oral fluoroquinolone, in urological infections. 1. Antibacterial activity: the MICs of fleroxacin against clinical isolates (185 strains of 12 species) from urinary tract infections, were compared with those of ofloxacin (OFLX) and norfloxacin (NFLX). Except against P.aeruginosa, the overall antibacterial activity of fleroxacin was excellent and similar to that of NFLX. 2. Clinical efficacy: the overall clinical efficacy according to the criteria of the Japanese UTI Committee was 100%(1/1) in acute uncomplicated cystitis and 75.6%(31/41) in chronic complicated UTI. Bacteriologically, 36 of 45 strains (80.0%) were eradicated. 3. Side effects: facial hot flushes were noted in one patient, but the symptom was mild and transient. With regard to laboratory findings, slight and transient elevations of GOT and GPT and of BUN and s-Cr were seen in one patient.",

keywords = "Fleroxacin",

author = "Yoshio Nishitani and Satoshi Uno and Daisuke Yamada and Yoshitsugu Nasu and Syunji Hayata and Masaya Tsugawa and Hiromi Kumon and Hiroyuki Ohmori",

year = "1990",

month = jan,

day = "1",

doi = "10.11250/chemotherapy1953.38.Supplement2_531",

language = "English",

volume = "38",

pages = "531--538",

journal = "Chemotherapy",

issn = "0009-3165",

}

TY - JOUR

T1 - Basic and clinical studies on fleroxacin in urological infections

AU - Nishitani, Yoshio

AU - Uno, Satoshi

AU - Yamada, Daisuke

AU - Nasu, Yoshitsugu

AU - Hayata, Syunji

AU - Tsugawa, Masaya

AU - Kumon, Hiromi

AU - Ohmori, Hiroyuki

PY - 1990/1/1

Y1 - 1990/1/1

N2 - We studied the antibacterial activity and clinical utility of fleroxacin, a new oral fluoroquinolone, in urological infections. 1. Antibacterial activity: the MICs of fleroxacin against clinical isolates (185 strains of 12 species) from urinary tract infections, were compared with those of ofloxacin (OFLX) and norfloxacin (NFLX). Except against P.aeruginosa, the overall antibacterial activity of fleroxacin was excellent and similar to that of NFLX. 2. Clinical efficacy: the overall clinical efficacy according to the criteria of the Japanese UTI Committee was 100%(1/1) in acute uncomplicated cystitis and 75.6%(31/41) in chronic complicated UTI. Bacteriologically, 36 of 45 strains (80.0%) were eradicated. 3. Side effects: facial hot flushes were noted in one patient, but the symptom was mild and transient. With regard to laboratory findings, slight and transient elevations of GOT and GPT and of BUN and s-Cr were seen in one patient.

AB - We studied the antibacterial activity and clinical utility of fleroxacin, a new oral fluoroquinolone, in urological infections. 1. Antibacterial activity: the MICs of fleroxacin against clinical isolates (185 strains of 12 species) from urinary tract infections, were compared with those of ofloxacin (OFLX) and norfloxacin (NFLX). Except against P.aeruginosa, the overall antibacterial activity of fleroxacin was excellent and similar to that of NFLX. 2. Clinical efficacy: the overall clinical efficacy according to the criteria of the Japanese UTI Committee was 100%(1/1) in acute uncomplicated cystitis and 75.6%(31/41) in chronic complicated UTI. Bacteriologically, 36 of 45 strains (80.0%) were eradicated. 3. Side effects: facial hot flushes were noted in one patient, but the symptom was mild and transient. With regard to laboratory findings, slight and transient elevations of GOT and GPT and of BUN and s-Cr were seen in one patient.

KW - Fleroxacin

UR - http://www.scopus.com/inward/record.url?scp=0025667177&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025667177&partnerID=8YFLogxK

U2 - 10.11250/chemotherapy1953.38.Supplement2_531

DO - 10.11250/chemotherapy1953.38.Supplement2_531

M3 - Article

AN - SCOPUS:0025667177

VL - 38

SP - 531

EP - 538

JO - Chemotherapy

JF - Chemotherapy

SN - 0009-3165

ER -

Basic and clinical studies on fleroxacin in urological infections

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Cite this